KM-819

FAScinate Therapeutics Inc. · Phase 2 active Small molecule

At a glance

Generic name	KM-819
Sponsor	FAScinate Therapeutics Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease (PHASE2)
Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA) (PHASE2)
Phase I, KM-819 in Healthy Subjects for Parkinson's Disease (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KM-819 CI brief — competitive landscape report
KM-819 updates RSS · CI watch RSS
FAScinate Therapeutics Inc. portfolio CI